Bio X Cell Biosimilar Antibody, Human PD-L1, IgG1, 150 kDa

Supplier:  Bio X Cell SIM0009R001MG

This non-therapeutic biosimilar antibody utilizes the same variable regions as the therapeutic antibody Atezolizumab, making it suitable for research applications. It targets human PD-L1 (programmed death ligand 1), also known as B7-H1 or CD274, and is designed to block its interaction with PD-1 and CD80, which is important in tumor immune evasion.

• Non-therapeutic biosimilar for research.
• Reacts with human PD-L1, B7-H1, or CD274.
• Molecular weight: 150 kDa.
• Purity: ≥95%.
• Endotoxin: ≤0.5 EU/mg.
• Sterility: 0.2 μm filtration.
• Produced in an animal-free facility.
• Purified by Protein A.
• Formulation: PBS, pH 7.0, no stabilizers or preservatives.
• Applications: in vivo PD-L1 blockade, flow cytometry, western blot.
• Storage: 4°C, do not freeze.
• Aggregation: <5%.

Catalog No. NC1959903